We are a clinical stage biopharmaceutical company focused on harnessing powerful biology underlying major diseases to develop transformative therapeutics for patients.
We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines.
We aspire to operate one of our industry’s most productive research and development engines and have built a robust pipeline of drug candidates – several of which are in clinical development – to address a spectrum of large, unmet medical needs. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. However, we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines.
Aug 25, 2019 12:24 AM EDT
Copyright West LLC. Minimum 15 minutes delayed.
News and Events
NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial ResultsRead more
NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare ConferenceRead more
NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes AssociationRead more
More events are coming soon.